Orchestra BioMed (OBIO) Insider David Pacitti Buys 17,327 Shares

Insider Buying and Selling at Orchestra BioMed Holdings, Inc.

David Pacitti purchased 17,327 shares of Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO) on June 23, 2026. This transaction came alongside a wave of similar purchases from multiple company insiders on the exact same day, reflecting shared alignment among leadership.

A Broader Look at Insider Activity

The June 23 purchases brought several key figures further into the stock. John Mack and Mack John Prosper each picked up 34,653 shares. Meanwhile, Jason Aryeh and Chris Cleary both acquired 42,553 shares apiece. Pamela Ann Connealy matched David Pacitti's purchase by picking up 17,327 shares on that same date.

Stock Performance and Recent Trading

At the time of the transaction, shares of Orchestra BioMed traded near $3.98. The stock has seen a 52-week range spanning from a low of $2.20 up to a high of $6.30. Its 50-day moving average sits at $4.72, while the 200-day moving average rests close to $4.33. The company holds a market capitalization of roughly $375.66 million and currently shows no positive P/E ratio as it operates at a loss.

Wall Street Analyst Views

Analyst firms have remained active with their outlooks on the biomedical company over the past few months. On August 11, 2026, Piper Sandler reiterated its overweight rating while raising its price target to $10.00 from $9.00. Later, on September 10, 2026, BTIG upgraded the stock to a buy with a $10.00 price target. Most recently, on September 15, 2026, B. Riley Securities maintained its buy rating and lifted its target to $11.00 from $10.00. Across seven analyst opinions, the stock currently holds a consensus strong buy rating with a mean price target of $12.14.

What Orchestra BioMed Does

Orchestra BioMed Holdings, Inc. is a New Hope, Pennsylvania-based biomedical firm focused on therapeutic products for cardiovascular and vascular diseases. Its candidates include bioelectronic therapies for lowering blood pressure and device systems designed to treat atherosclerotic artery disease. The company works alongside major partners like Medtronic and Terumo to develop and commercialize these treatments.

What's Ahead for OBIO

Investors will likely keep an eye on upcoming clinical updates and the company's scheduled financial results release on November 5, 2026. These disclosures will provide further clarity on how leadership's internal investments align with ongoing product development.